• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Bruush Oral Care Inc. (Amendment)

    2/13/23 5:24:24 PM ET
    $BRSH
    Medical/Dental Instruments
    Health Care
    Get the next $BRSH alert in real time by email
    SC 13G/A 1 g083402_sc-13ga.htm SC 13G/A

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

    Bruush Oral Care Inc.

    (Name of Issuer)

     

    Common Stock, no par value

    (Title of Class of Securities)

     

    11750K203

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 11750K203

      13G   Page 2 of 9 Pages
       
    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Ionic Ventures, LLC
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☐
    (b)    ☒
    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    California, United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6.

    SHARED VOTING POWER

     

    414,834 (1)

    7. SOLE DISPOSITIVE POWER
     
    0
    8.

    SHARED DISPOSITIVE POWER

     

    414,834 (1)

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    414,834 (1)

    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.99%
    12. TYPE OF REPORTING PERSON (see instructions)

    OO
    (1)As more fully described in Item 4, this does not give full effect to warrants owned by the reporting person subject to a beneficial ownership blocker.

     

     

     

     

    CUSIP No. 11750K203

      13G   Page 3 of 9 Pages
       
    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Brendan O’Neil
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☐
    (b)    ☒
    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6.

    SHARED VOTING POWER

     

    414,834 (1)

    7. SOLE DISPOSITIVE POWER
     
    0
    8.

    SHARED DISPOSITIVE POWER

     

    414,834 (1)

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    414,834 (1)

    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.99%
    12. TYPE OF REPORTING PERSON (see instructions)

    IN
    (1)As more fully described in Item 4, this does not give full effect to warrants owned by the reporting person subject to a beneficial ownership blocker.

     

     

     

     

    CUSIP No. 11750K203   13G   Page 4 of 9 Pages
       
    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Keith Coulston
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☐
    (b)    ☒
    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6.

    SHARED VOTING POWER

     

    414,834 (1)

    7. SOLE DISPOSITIVE POWER
     
    0
    8.

    SHARED DISPOSITIVE POWER

     

    414,834 (1)

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    414,834 (1)

    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.99%
    12. TYPE OF REPORTING PERSON (see instructions)

    IN
    (1)As more fully described in Item 4, this does not give full effect to warrants owned by the reporting person subject to a beneficial ownership blocker.

     

     

     

     

    CUSIP No. 11750K203   13G   Page 5 of 9 Pages

     

    Item 1(a). Name of Issuer:

     

    Bruush Oral Care Inc. (the “Issuer”).

     

    Item 1(b). Address of Issuer’s Principal Executive Offices:

     

    The Issuer’s principal executive offices are located at 128 West Hastings Street, Unit 210, Vancouver, British Columbia V6B 1G8 Canada.

     

    Item 2(a). Names of Persons Filing:

     

    This statement is filed by:
       
      (i) Ionic Ventures LLC, a California limited liability company (“Ionic”);
       
      (ii) Brendan O’Neil (“Mr. O’Neil”); and
       
      (iii)  Keith Coulston (“Mr. Coulston”).

     

    The foregoing persons are hereinafter sometimes collectively referred to as the (“Reporting Persons”). Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

     

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act.

     

    The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.  

     

    Item 2(b). Address of Principal Business Office or, if none, Residence:

     

    The principal business address of each of the Reporting Persons is 3053 Fillmore St, Suite 256, San Francisco, CA 94123.

     

    Item 2(c). Citizenship:

     

    Ionic is a limited liability company organized under the laws of California. Each of Mr. O’Neil and Mr. Coulston is a citizen of the United States.

     

    Item 2(d). Title of Class of Securities:

     

    The title of the class of securities to which this statement relates is the Common Stock, no par value.

     

    Item 2(e). CUSIP Number: 11750K203

     

     

     

     

    CUSIP No. 11750K203   13G   Page 6 of 9 Pages

     

    Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

     

    Not applicable.

     

    Item 4. Ownership.

     

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G and is incorporated herein by reference for each such Reporting Person. The ownership percentages reported are based on (i) 8,150,875 shares of Common Stock outstanding as reported in the Issuer’s Registration Statement on Form F-1, filed with the U.S. Securities and Exchange Commission on December 27, 2022 and (ii) 162,430 shares of Common Stock that are issuable upon exercise of warrants (the “Warrants”) that are held by the Reporting Persons, subject to a blocker (the “Blocker”).

     

    As of December 31, 2022, the Reporting Persons hold (i) 414,834 shares of Common Stock and (ii) an additional 1,122,525 shares of Common Stock issuable upon full exercise of the Warrants held by the Reporting Persons. Due to the Blocker, the Reporting Persons are prohibited from exercising the Warrants into shares of Common Stock if, as a result of such exercise, the holder, together with its affiliates and any persons acting as a group together with such holder or any of such affiliates, would beneficially own more than 4.99% of the total number of shares of Common Stock then issued and outstanding immediately after giving effect to the exercise. Consequently, as of the date of the event which requires the filing of this statement, the Reporting Persons were not able to exercise all of the Warrants due to the Blocker.

     

    As of December 31, 2022, Ionic is the beneficial owner of 414,834 shares of Common Stock (the “Shares”). Ionic has the power to dispose of and the power to vote the Shares beneficially owned by it, which power may be exercised by its managers, Mr. O’Neil and Mr. Coulston. Mr. O’Neil and Mr. Coulston, as managers of Ionic, have shared power to vote and/or dispose of the Shares beneficially owned by Ionic. Neither Mr. O’Neil nor Mr. Coulston directly owns any Common Stock of the Issuer. By reason of the provisions of Rule 13d-3 of the Act, each of Mr. O’Neil and Mr. Coulston may be deemed to beneficially own the Shares beneficially owned by Ionic.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

     

     

     

    CUSIP No. 11750K203   13G   Page 7 of 9 Pages

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    CUSIP No. 11750K203   13G   Page 8 of 9 Pages

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 13, 2023 IONIC VENTURES, LLC
       
      /s/ Keith Coulston
      Name: Keith Coulston
      Title: Partner
       
      /s/ Brendan O’Neil
      Brendan O’Neil
       
      /s/ Keith Coulston
      Keith Coulston

     

     

     

     

    CUSIP No. 11750K203   13G   Page 9 of 9 Pages

     

    EXHIBIT 1

     

    JOINT FILING AGREEMENT

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. The undersigned hereby further agree that this Joint Filing Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original, but all of which counterparts shall together constitute one and the same instrument.

     

    Date: February 13, 2023 IONIC VENTURES, LLC
       
      /s/ Keith Coulston
      Name: Keith Coulston
      Title: Partner
       
      /s/ Brendan O’Neil
      Brendan O’Neil
       
      /s/ Keith Coulston
      Keith Coulston

     

     

    Get the next $BRSH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BRSH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BRSH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Brüush Receives Additional Delisting Notification to Address at Hearing

      VANCOUVER, BC / ACCESSWIRE / April 19, 2024 / Bruush Oral Care Inc. (NASDAQ:BRSH) (the "Company"), today announced that it received a notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market, LLC ("Nasdaq") on April 15, 2024 notifying the Company that because it is not compliant with Nasdaq's audit committee requirements as set forth in Listing Rule 5605 (the "Audit Committee Requirements"), this deficiency serves as an additional basis for delisting the Company's securities from Nasdaq. This deficiency will be considered by the Hearings Panel (the "Panel") at a hearing that has been scheduled for April 25, 2024 (the "Hearing") to address the Company's othe

      4/19/24 2:45:00 AM ET
      $BRSH
      Medical/Dental Instruments
      Health Care
    • Brüush Receives Additional Delisting Notification to Address at Hearing

      VANCOUVER, BC / ACCESSWIRE / March 25, 2024 / Bruush Oral Care Inc. (NASDAQ:BRSH) (the "Company"), today announced that it has received a notice from the Listing Qualifications Department of The Nasdaq Stock Market, LLC ("Nasdaq") on March 20, 2024 notifying the Company that because the Company is delinquent in filing its annual report on Form 20-F for the year ended October 31, 2023, this deficiency serves as an additional basis for delisting the Company's securities from Nasdaq per Listing Rule 5810(d). This deficiency will be considered by the Hearings Panel (the "Panel") at a hearing that has been scheduled for April 25, 2024 to address the Company's other current deficiencies.As previou

      3/25/24 6:00:00 PM ET
      $BRSH
      Medical/Dental Instruments
      Health Care
    • Brüush Receives Nasdaq Delisting Notification and Files to Appeal

      VANCOUVER, BC / ACCESSWIRE / March 1, 2024 / Bruush Oral Care Inc. (NASDAQ:BRSH) (the "Company"), today announced that it has received a notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market, LLC ("Nasdaq") on February 27, 2024 notifying the Company of Nasdaq's determination to delist the Company's common shares from The Nasdaq Capital Market because the Company's common shares had a closing bid price of $0.10 or less for ten consecutive trading days as of February 26, 2024, which triggered a notice of delisting pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the "Low Priced Stocks Rule").In addition to the Low Priced Stocks Rule delisting notice, as

      3/1/24 11:20:00 PM ET
      $BRSH
      Medical/Dental Instruments
      Health Care

    $BRSH
    Financials

    Live finance-specific insights

    See more
    • Arrive Acquires AirBox Technologies in Advance of Brüush Merger

      Acquisition Broadens Patent Portfolio and Propels Arrive's Smart Mailbox as a Service CapabilitiesVANCOUVER, BC and INDIANAPOLIS, IN / ACCESSWIRE / December 18, 2023 / Bruush Oral Care Inc. (NASDAQ:BRSH) ("Brüush") announced today that its pending merger partner, Arrive Technology Inc. ("Arrive"), a technology company focused on facilitating the last inch of the last-mile for autonomous delivery, has acquired AirBox Technologies ("AirBox"). This acquisition includes AirBox's patent portfolio, which Arrive believes will broaden the capabilities of its high-tech mailbox system designed for autonomous and conventional package delivery. In addition to acquiring the patent portfolio, AirBox's CEO

      12/18/23 7:00:00 AM ET
      $BRSH
      Medical/Dental Instruments
      Health Care

    $BRSH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Bruush Oral Care Inc. (Amendment)

      SC 13D/A - Bruush Oral Care Inc. (0001913210) (Subject)

      2/23/24 5:15:27 PM ET
      $BRSH
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Bruush Oral Care Inc. (Amendment)

      SC 13D/A - Bruush Oral Care Inc. (0001913210) (Subject)

      2/16/24 5:15:16 PM ET
      $BRSH
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Bruush Oral Care Inc. (Amendment)

      SC 13G/A - Bruush Oral Care Inc. (0001913210) (Subject)

      2/14/24 2:43:40 PM ET
      $BRSH
      Medical/Dental Instruments
      Health Care

    $BRSH
    Leadership Updates

    Live Leadership Updates

    See more
    • Brüush Appoints New Chief Financial Officer

      VANCOUVER, BC / ACCESSWIRE / April 4, 2023 / Bruush Oral Care Inc. (NASDAQ:BRSH) ("Brüush" or the "Company"), a direct-to-consumer leader in the oral care category, has appointed Mandeek Manhas as the new Chief Financial Officer, the Company announced today.With an extensive background in finance and accounting, Mr. Manhas brings over 17 years of experience to this role.Prior to joining Brüush, Mr. Manhas held leadership positions in two reputable organizations, including a private real estate company with over $2.5 billion in asset value and a publicly listed, multi-national mining company with advanced development stage and exploration projects. Mr. Manhas has also spent eleven years in au

      4/4/23 8:45:00 AM ET
      $BRSH
      Medical/Dental Instruments
      Health Care
    • PARVIS INVEST INC. AND GRAVITAS II CAPITAL CORP. RECEIVE CONDITIONAL APPROVAL OF REVERSE TAKEOVER TRANSACTION AND FILE FILING STATEMENT

      VANCOUVER, BC, March 2, 2023 /CNW/ - Gravitas II Capital Corp. ("Gravitas II") (TSXV:GII) and Parvis Invest Inc. ("Parvis") are pleased to announce that, in connection with their previously announced proposed business combination (the "Transaction") as described in Gravitas II's news releases dated November 3, 2022 and August 29, 2022, the TSX Venture Exchange Inc. (the "Exchange") has conditionally approved the Transaction and the listing of the common shares of Gravitas II, following closing of the Transaction (the "Resulting Issuer"). The Transaction is expected to close on March 3, 2023, following which the common shares of the Resulting Issuer are expected to begin trading under the sym

      3/2/23 7:57:00 AM ET
      $BRSH
      $GOOGL
      Medical/Dental Instruments
      Health Care
      Computer Software: Programming Data Processing
      Technology
    • Brüush Appoints New Vice President of Sales & Business Development

      Mark Humphrey will focus on expanding Brüush's distribution footprint into new channelsVANCOUVER, BC / ACCESSWIRE / November 3, 2022 / Bruush Oral Care Inc. (NASDAQ:BRSH), a direct-to-consumer leader in the oral care category, has appointed Mark Humphrey to the key role of Vice President - Sales & Business Development, the company announced today. Mr. Humphrey will help Brüush drive sales growth, with a particular focus on expanding the brand's distribution footprint into new channels and evaluating strategic partnerships with other companies.Mr. Humphrey brings over 20 years of experience in leadership positions at high-growth organizations, where he primarily focused on revenue generation.

      11/3/22 9:30:00 AM ET
      $BRSH
      Medical/Dental Instruments
      Health Care

    $BRSH
    SEC Filings

    See more
    • SEC Form 6-K filed by Bruush Oral Care Inc.

      6-K - Bruush Oral Care Inc. (0001913210) (Filer)

      6/20/24 9:00:44 PM ET
      $BRSH
      Medical/Dental Instruments
      Health Care
    • SEC Form 6-K filed by Bruush Oral Care Inc.

      6-K - Bruush Oral Care Inc. (0001913210) (Filer)

      4/18/24 5:25:04 PM ET
      $BRSH
      Medical/Dental Instruments
      Health Care
    • SEC Form 6-K filed by Bruush Oral Care Inc.

      6-K - Bruush Oral Care Inc. (0001913210) (Filer)

      3/22/24 5:15:05 PM ET
      $BRSH
      Medical/Dental Instruments
      Health Care